Boston Scientific Q1 Revenue Rises 11.2% to $5.2B, Cuts 2026 Growth to 7%–8.5%
Boston Scientific reported Q1 revenue of $5.2 billion, up 11.2% year-over-year, led by a 13.5% surge in cardiovascular sales to $3.5 billion. The company trimmed its full-year 2026 growth outlook to 7–8.5% from 10.5–11.5% and lowered EPS guidance to $3.34–$3.41.
1. Q1 Financial Results
Boston Scientific delivered Q1 revenue of $5.2 billion, marking an 11.2% year-over-year increase. Cardiovascular sales drove the upswing with $3.5 billion—up 13.5%—while endoscopy revenue reached $736 million (up 9.4%) and neuromodulation hit $318 million (up 17.4%).
2. Revised Full-Year Outlook
Management narrowed 2026 revenue growth expectations to 7–8.5% from 10.5–11.5% and reduced earnings guidance to $3.34–$3.41 per share from $3.43–$3.49. The adjustment reflects competitive dynamics offset by strength in the Farapulse PFA catheter and mapping portfolio.
3. Share Price Reaction
Shares closed at $64.87, a rise of 8.9% from the prior session’s $59.52 close, lifting market capitalization to approximately $96.4 billion. Investor confidence remained buoyant despite the tempered outlook.
4. Cardiovascular Segment and Market Context
The electrophysiology ablation catheter market is projected to expand from $6.1 billion in 2025 to $17.6 billion by 2035, underpinning growth for the Farapulse PFA system. Medtronic’s latest quarter saw $3.46 billion in revenue, up 13.8% year-over-year, with PFA-driven cardiac ablation sales growing 80%.